Companies / India
If you would like to subscribe to Western Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Western Europe Pharma & Healthcare Insight please click on the trial link below.
DSM Opens Huge Antibiotics Facility
September 2006 | FDI AlertSorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Western Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Western Europe Pharma & Healthcare Insight please click on the trial link below.
Exploiting the sub-continent's low-cost base, Netherlands-based DSM Anti-Infectives has opened a US$500mn plant in India to produce Purimox (amoxicillin trihydrate). DSM has annual sales of US$100mn in India and is hoping to capture a 10% share of the country's antibiotics market, which is currently valued at US$1.9bn and forecast to grow significantly in the mid-term.